JP2012507033A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507033A5
JP2012507033A5 JP2011534536A JP2011534536A JP2012507033A5 JP 2012507033 A5 JP2012507033 A5 JP 2012507033A5 JP 2011534536 A JP2011534536 A JP 2011534536A JP 2011534536 A JP2011534536 A JP 2011534536A JP 2012507033 A5 JP2012507033 A5 JP 2012507033A5
Authority
JP
Japan
Prior art keywords
spectrum
monoclonal antibody
growth factor
factor receptor
epidermal growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011534536A
Other languages
English (en)
Japanese (ja)
Other versions
JP4997345B2 (ja
JP2012507033A (ja
Filing date
Publication date
Priority claimed from US12/321,394 external-priority patent/US7858390B2/en
Application filed filed Critical
Publication of JP2012507033A publication Critical patent/JP2012507033A/ja
Publication of JP2012507033A5 publication Critical patent/JP2012507033A5/ja
Application granted granted Critical
Publication of JP4997345B2 publication Critical patent/JP4997345B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011534536A 2009-01-20 2009-11-20 Egfr経路を標的にする薬物による治療のための結腸直腸癌患者の選択 Expired - Fee Related JP4997345B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/321,394 US7858390B2 (en) 2006-03-31 2009-01-20 Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US12/321,394 2009-01-20
PCT/US2009/006267 WO2010085234A1 (en) 2009-01-20 2009-11-20 Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway

Publications (3)

Publication Number Publication Date
JP2012507033A JP2012507033A (ja) 2012-03-22
JP2012507033A5 true JP2012507033A5 (https=) 2012-05-10
JP4997345B2 JP4997345B2 (ja) 2012-08-08

Family

ID=41571343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534536A Expired - Fee Related JP4997345B2 (ja) 2009-01-20 2009-11-20 Egfr経路を標的にする薬物による治療のための結腸直腸癌患者の選択

Country Status (10)

Country Link
US (1) US7858390B2 (https=)
EP (1) EP2347261B1 (https=)
JP (1) JP4997345B2 (https=)
KR (1) KR101131231B1 (https=)
AU (1) AU2009338173B2 (https=)
CA (1) CA2744394A1 (https=)
ES (1) ES2392805T3 (https=)
IL (1) IL211944A (https=)
TW (1) TWI366671B (https=)
WO (1) WO2010085234A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858390B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
CN102770760A (zh) * 2010-02-24 2012-11-07 佰欧迪塞克斯公司 利用质谱分析选择施用治疗剂的癌症患者
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
AU2013287262A1 (en) 2012-07-05 2015-02-26 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
WO2017011439A1 (en) 2015-07-13 2017-01-19 Biodesix, Inc. Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods
CA3011719A1 (en) 2016-01-21 2017-07-27 Protein Dynamic Solutions Llc Method and system for spectral data analysis
US11710539B2 (en) 2016-02-01 2023-07-25 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
WO2017176423A1 (en) 2016-04-08 2017-10-12 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
WO2018129301A1 (en) * 2017-01-05 2018-07-12 Biodesix, Inc. Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
US20210369775A1 (en) 2017-12-15 2021-12-02 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
US12094587B2 (en) 2018-03-29 2024-09-17 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
US20230386662A1 (en) * 2020-10-19 2023-11-30 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Rapid and direct identification and determination of urine bacterial susceptibility to antibiotics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101107765B1 (ko) 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
AU2004248140A1 (en) 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
US20050267689A1 (en) 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
WO2005010492A2 (en) 2003-07-17 2005-02-03 Yale University Classification of disease states using mass spectrometry data
US20090204334A1 (en) 2004-03-30 2009-08-13 Eastern Virginia Medical School Lung cancer biomarkers
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
CA2612183C (en) * 2005-06-28 2015-08-11 Genentech, Inc. Egfr and kras mutations
WO2007109571A2 (en) * 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858390B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway

Similar Documents

Publication Publication Date Title
JP2012507033A5 (https=)
JP2011513728A5 (https=)
Onaitis et al. Prediction of long-term survival after lung cancer surgery for elderly patients in The Society of Thoracic Surgeons General Thoracic Surgery Database
Quezada et al. Omics-based biomarkers: current status and potential use in the clinic
JP2011506917A5 (https=)
JP2015528110A5 (https=)
JP2013520681A5 (https=)
IL204922A0 (en) Methods for detecting major adverse cardiovascular and cerebrovascular events
WO2007109881A8 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
BR0312534A (pt) método de identificação de um tumor, método para a identificação de células de tumor, método para prever a resposta de um indivìduo diagnosticado com um tumor de her2-positivo, método para a identificação de um individuo responsivo ao tratamento com anticorpo anti-her2 e métodos de tratamento de um paciente e artigo de manufatura
WO2012047899A3 (en) Novel dna hypermethylation diagnostic biomarkers for colorectal cancer
EP2707710A1 (en) Diagnosis of cancer
JP2009538607A5 (https=)
JP2011516046A5 (https=)
JP2009534667A5 (https=)
Mazzone et al. Progress in the development of volatile exhaled breath signatures of lung cancer
GB201222576D0 (en) Method for diagnosing lung cancer
CN106092990A (zh) 一种宁夏枸杞的三维荧光光谱鉴别方法
WO2015100459A3 (en) Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2010037859A3 (en) Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
Yang et al. Decreased macrophage inflammatory protein (MIP)‐1α and MIP‐1β increase the risk of developing nasopharyngeal carcinoma
WO2011037827A3 (en) Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual
WO2012131092A3 (en) Method and kits for the prediction of response/nonresponse to the treatment with an anti-egfr antibody in patients with colorectal cancer of all uicc stages
Michalčíková et al. A selected ion flow tube study of the ion molecule association reactions of protonated (MH+), nitrosonated (MNO+) and dehydroxidated (M− OH)+ carboxylic acids (M) with H2O
ES2530357T3 (es) Método para detectar una infección con plasmodio